Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17917288 | 0.87 | SAT1 (0.33) | SIGMAR1 | |
| SCHEMBL18355945 | 0.87 | SAT1 (0.33) | SIGMAR1 | |
| SCHEMBL24303411 | 0.86 | SIGMAR1 (0.53) | SIGMAR1CYP1A2EPHX1KDM1AMAOA | |
| SCHEMBL10293236 | 0.80 | CYP1A2 (0.45) | SIGMAR1CYP1A2EPHX1KDM1AMAOA | |
| SCHEMBL17917293 | 0.79 | SAT1 (0.38) | — | |
| SCHEMBL13762265 | 0.78 | HRH3 (0.39) | EPHX1KMT2A | |
| SCHEMBL24171126 | 0.78 | NAMPT (0.34) | SIGMAR1 | |
| SCHEMBL24170962 | 0.78 | NAMPT (0.34) | SIGMAR1 | |
| SCHEMBL2524987 | 0.78 | ADH1B (0.43) | SIGMAR1CYP1A2EPHX1 | |
| SCHEMBL24853530 | 0.77 | KDM1A (0.39) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227340-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180072712-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072712-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-9862715-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160083375-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-24 | — | — | US | disclosed |
| US-9242975-B2 | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242976-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-8987311-B2 | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150045347-A1 | TRIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-02-12 | — | — | US | disclosed |
| EP-0986384-B1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20110178061-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-7888384-B2 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888384-B2 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090253682-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-08 | — | — | US | disclosed |
| US-7569604-B2 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-08-04 | — | — | US | disclosed |
| EP-0986384-A4 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |
| EP-0986384-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998050029-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253682-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | CACNA1D, ORAI1, CACNA1C | SIGMAR1 2085/4885CYP1A2 3497/4885EPHX1 2430/4885 |
| US-20150045347-A1 | TRIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | IRAK4, IRAK3, IRAK1 | SIGMAR1 3718/4885CYP1A2 4520/4885EPHX1 3867/4885 |
| US-20180072712-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | IRAK4, IRAK1, IRAK3 | SIGMAR1 2639/4885CYP1A2 4626/4885EPHX1 3441/4885 |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | SIGMAR1 286/4885CYP1A2 84/4885EPHX1 3772/4885 |
| US-20110178061-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | CACNA1D, ORAI1, CACNA1C | SIGMAR1 2085/4885CYP1A2 3497/4885EPHX1 2430/4885 |
| US-10227340-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | IRAK4, IRAK1, IRAK3 | SIGMAR1 2639/4885CYP1A2 4626/4885EPHX1 3441/4885 |
| US-20160083375-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | IRAK4, IRAK1, IRAK3 | SIGMAR1 2639/4885CYP1A2 4626/4885EPHX1 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.